Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, comments on some of the highlights in chronic lymphocytic leukemia (CLL) from this year's ASH meeting, including a session on the time-limited combination of ibrutinib and venetoclax, and the prognostic value of undetectable measurable residual disease (MRD) in patients treated with this combination and with mutated IgHV. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
